146 related articles for article (PubMed ID: 15577328)
1. Serum bcl-2 and survivin levels in melanoma.
Tas F; Duranyildiz D; Argon A; Oguz H; Camlica H; Yasasever V; Topuz E
Melanoma Res; 2004 Dec; 14(6):543-6. PubMed ID: 15577328
[TBL] [Abstract][Full Text] [Related]
2. Serum and urine survivin levels in breast cancer.
Guney N; Soydine HO; Derin D; Tas F; Camlica H; Duranyildiz D; Yasasever V; Topuz E
Med Oncol; 2006; 23(3):335-9. PubMed ID: 17018890
[TBL] [Abstract][Full Text] [Related]
3. Survivin, bcl-2, bax, and bcl-X gene expression in sentinel lymph nodes from melanoma patients.
Gradilone A; Gazzaniga P; Ribuffo D; Scarpa S; Cigna E; Vasaturo F; Bottoni U; Innocenzi D; Calvieri S; Scuderi N; Frati L; Aglianò AM
J Clin Oncol; 2003 Jan; 21(2):306-12. PubMed ID: 12525523
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic implications of the kinetics of immunomodulation during single or combined treatment of melanoma patients with dacarbazine and interferon-alpha.
Konjević G; Jović V; Radulović S; Jelić S; Dzodić R; Spuzić I
Neoplasma; 2001; 48(3):175-81. PubMed ID: 11583285
[TBL] [Abstract][Full Text] [Related]
5. Melanoma inhibitory activity (MIA), a serological marker of malignant melanoma.
Bosserhoff AK; Dreau D; Hein R; Landthaler M; Holder WD; Buettner R
Recent Results Cancer Res; 2001; 158():158-68. PubMed ID: 11092043
[TBL] [Abstract][Full Text] [Related]
6. Lack of prognostic significance of survivin, survivin-deltaEx3, survivin-2B, galectin-3, bag-1, bax-alpha and MRP-1 mRNAs in breast cancer.
O'Driscoll L; Linehan R; M Kennedy S; Cronin D; Purcell R; Glynn S; W McDermott E; D Hill A; J O'Higgins N; Parkinson M; Clynes M
Cancer Lett; 2003 Nov; 201(2):225-36. PubMed ID: 14607338
[TBL] [Abstract][Full Text] [Related]
7. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.
Bedikian AY; Millward M; Pehamberger H; Conry R; Gore M; Trefzer U; Pavlick AC; DeConti R; Hersh EM; Hersey P; Kirkwood JM; Haluska FG;
J Clin Oncol; 2006 Oct; 24(29):4738-45. PubMed ID: 16966688
[TBL] [Abstract][Full Text] [Related]
8. Correlation of local and systemic expression of survivin with histopathological parameters of cutaneous melanoma.
Jović M; Cerović S; Zolotarevska L; Gačević M; Stanojević I; Miller K; Đukić M; Saso L; Jauković L; Vojvodić D
Vojnosanit Pregl; 2016 Nov; 73(11):1022-9. PubMed ID: 29328641
[TBL] [Abstract][Full Text] [Related]
9. Influence of COX-2 inhibition by rofecoxib on serum and tumor progastrin and gastrin levels and expression of PPARgamma and apoptosis-related proteins in gastric cancer patients.
Konturek PC; Konturek SJ; Bielanski W; Kania J; Zuchowicz M; Hartwich A; Rehfeld JF; Hahn EG
Dig Dis Sci; 2003 Oct; 48(10):2005-17. PubMed ID: 14627349
[TBL] [Abstract][Full Text] [Related]
10. Oblimersen in the treatment of metastatic melanoma.
Tarhini AA; Kirkwood JM
Future Oncol; 2007 Jun; 3(3):263-71. PubMed ID: 17547520
[TBL] [Abstract][Full Text] [Related]
11. The value of serum bcl-2 levels in advanced epithelial ovarian cancer.
Tas F; Duranyildiz D; Oguz H; Camlica H; Yasasever V; Topuz E
Med Oncol; 2006; 23(2):213-7. PubMed ID: 16720921
[TBL] [Abstract][Full Text] [Related]
12. Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets.
Grossman D; Altieri DC
Cancer Metastasis Rev; 2001; 20(1-2):3-11. PubMed ID: 11831644
[TBL] [Abstract][Full Text] [Related]
13. [Expression of survivin, Fas, bcl-2 and bax in bone marrow cells from acute myeloid leukemia patients and its clinical significance].
Lin FR; Wang Y; Wang RQ; Du XY; Guo XN; Ren JH; Guo XL; Yao L; Yao EG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Jun; 11(3):259-62. PubMed ID: 12844408
[TBL] [Abstract][Full Text] [Related]
14. Prognostic implications of protein S-100beta serum levels in the clinical outcome of high-risk melanoma patients.
Domingo-Domènech J; Castel T; Auge JM; Garcia-Albeniz XA; Conill C; Puig S; Vilella R; Matas J; Malvehy J; Gascón P; Mellado B; Molina R
Tumour Biol; 2007; 28(5):264-72. PubMed ID: 17962723
[TBL] [Abstract][Full Text] [Related]
15. Combined evaluation of expression of telomerase, survivin, and anti-apoptotic Bcl-2 family members in relation to loss of differentiation and apoptosis in human head and neck cancers.
Sharma H; Sen S; Mathur M; Bahadur S; Singh N
Head Neck; 2004 Aug; 26(8):733-40. PubMed ID: 15287041
[TBL] [Abstract][Full Text] [Related]
16. Circulating levels of vascular endothelial growth factor (VEGF), matrix metalloproteinase-3 (MMP-3), and BCL-2 in malignant melanoma.
Tas F; Duranyildiz D; Oguz H; Camlica H; Yasasever V; Topuz E
Med Oncol; 2008; 25(4):431-6. PubMed ID: 18363112
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and predictive value of YKL-40 in stage IIB-III melanoma.
Krogh M; Christensen I; Bouwhuis M; Johansen JS; Nørgaard P; Schmidt H; Hansson J; Suciu S; Eggermont AM; Bastholt L;
Melanoma Res; 2016 Aug; 26(4):367-76. PubMed ID: 27076041
[TBL] [Abstract][Full Text] [Related]
18. Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model.
Thallinger C; Wolschek MF; Wacheck V; Maierhofer H; Günsberg P; Polterauer P; Pehamberger H; Monia BP; Selzer E; Wolff K; Jansen B
J Invest Dermatol; 2003 Jun; 120(6):1081-6. PubMed ID: 12787138
[TBL] [Abstract][Full Text] [Related]
19. Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study).
Fusi A; Collette S; Busse A; Suciu S; Rietz A; Santinami M; Kruit WH; Testori A; Punt CJ; Dalgleish AG; Spatz A; Eggermont AM; Keilholz U
Eur J Cancer; 2009 Dec; 45(18):3189-97. PubMed ID: 19793643
[TBL] [Abstract][Full Text] [Related]
20. Quantitative evaluation of the apoptosis regulating genes Survivin, Bcl-2 and Bax in inflammatory and malignant pleural lesions.
Falleni M; Pellegrini C; Marchetti A; Roncalli M; Nosotti M; Palleschi A; Santambrogio L; Coggi G; Bosari S
Lung Cancer; 2005 May; 48(2):211-6. PubMed ID: 15829320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
